Following publication of the Research Article by Nikki Heath, Xabier Osteikoetxea, Taiana Mia de Oliveria, Elisa Lázaro-Ibáñez, Olga Shatnyeva, Christina Schindler, Natalie Tigue, Lorenz M Mayr, Niek Dekker, Ross Overman & Rick Davies, titled ‘Endosomal escape enhancing compounds facilitate functional delivery of extracellular vesicle cargo’, which appeared in one of the November 2019 issues of Nanomedicine (Nanomedicine [Lond.] 14[21], 2799–2814 [2019]; DOI: 10.2217/nnm-2019-0061), it has been brought to our attention that the name of a compound has been incorrectly given throughout the text.
The compound name UNC10217832A appeared numerous times in the text, figures and figure legends. However, it should have instead appeared as UNC10217938A. This has now been corrected.
Further, the sentences “An analog of UNC10217832A (UNC10217938A) was used in vivo to aid delivery of ASOs and no significant toxicity was observed when used at 7.5 mg/kg [46]. If UNC10217832A proves to also be well tolerated with low toxicity in vivo, it could be a promising compound to use systemically or in conjunction with EV therapeutics,” have been rewritten as “UNC10217938A was used in vivo to aid delivery of ASOs and no significant toxicity was observed when used at 7.5 mg/kg [46]. If further work confirms UNC10217938A is well tolerated with low toxicity in vivo, it could be a promising compound to use systemically or in conjunction with EV therapeutics.”
The authors and editors of Nanomedicine would like to sincerely apologize for any confusion or inconvenience this may have caused our readers.